At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 7 enrolled
Drug / intervention
CX-8998drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2a, Safety, Tolerability, Pharmacokinetics, and Quantitative EEG Study of CX-8998 in Adolescents and Adults With Idiopathic Generalized Epilepsy With Absence Seizures
In Brief
A Phase 2 clinical trial evaluating CX-8998 for Epilepsy. Completed, enrolled 7 participants across 7 sites.
Detailed Summary
This is a Phase 2a, open-label study consisting of a screening period of up to 4 weeks and a 4-dose-titration treatment period to a dose of up to 10 mg twice daily (BID) of CX-8998, followed by a 1-week safety follow-up period after the last dose of study medication.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEpilepsy
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedJan 2018
Enrollment StartFeb 2018
Primary CompletionMar 2019
TodayJul 2026
First PostedJan 23, 2018
Enrollment StartFeb 25, 2018
Primary CompletionMar 29, 2019
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 8.4 years ago
Interventions
CX-8998drug
T-type calcium channel blocker